You can buy Niranib at the lowest price at Nextgen.ooo online pharmacy. Niraparib is an orally active PARP inhibitor developed by Tesaro for the treatment of ovarian cancer. FDA approval in March 2017. Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
 
Niraparib is an inhibitor of the poly-ADP-ribose polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, leading to DNA damage, apoptosis, and cell death. Enhanced cytotoxicity induced by niraparib was observed in tumor cell lines with or without BRCA1/2 deficiency. Niraparib reduced tumor growth in mouse xenograft models of BRCA1/2-deficient human cancer cell lines and in xenograft patient-derived tumor models with homologous recombination deficiency that had either mutated or wild-type BRCA1/2.